VANCOUVER, British Columbia — September 4, 2025 — Leads & Copy — Rakovina Therapeutics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, September 8-10, according to a press release.
Executive Chairman Jeffrey Bacha will present an overview of Rakovina’s research and development pipeline, corporate strategy, and upcoming milestones. The presentation will be accessible to registered conference attendees, with a recording made available on Rakovina’s website and social media channels following the event. Management will also participate in one-to-one meetings with institutional investors.
Rakovina has achieved milestones in the first half of 2025, including:
- Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting.
- Obtained DTC eligibility, streamlining investment for U.S. investors.
- Advanced the KT-5000AI program, yielding potent ATR inhibitor candidates from AI-enabled screening.
- Announced a non-binding Letter of Intent with Saudi-based NanoPalm Ltd. to form a joint venture.
The H.C. Wainwright conference will feature keynote speakers, investor meetings, and networking opportunities at the Lotte New York Palace Hotel, with both in-person and virtual participation available.
Rakovina Therapeutics is focused on developing cancer treatments using AI-powered technologies. They have a pipeline of DNA-damage response inhibitors and aim to advance drug candidates into human clinical trials.
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432
Source: Rakovina Therapeutics Inc.
